Literature DB >> 12498286

Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis.

David F Stein1, Malay Myaing.   

Abstract

Measurement of serum AFP can be useful in the diagnosis of hepatocellular carcinoma (HCC). AFP is a fetal protein that is not normally present in the serum of adults but is elevated in most patients with HCC. The diagnosis of HCC is generally made in patients with a mass lesion in a cirrhotic liver if the AFP is over 400 ng/ml. Unfortunately, AFP is elevated in other conditions such as nonseminomatous germ cell tumor, chronic hepatitis, cirrhosis, pregnancy, and hepatic metastasis. A high AFP cutoff value for HCC would increase the specificity of the test, but would decrease the sensitivity considerably. We report the case of a patient with HCV and cirrhosis with a markedly elevated AFP of 1257 ng/ml in whom no evidence of HCC could be found after a thorough radiologic and histologic evaluation. Despite a virologic nonresponse to IFN-alpha2b and ribavirin therapy, there was a complete normalization of AFP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498286     DOI: 10.1023/a:1021044803279

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Chronic hepatitis C and markedly elevated serum alpha-fetoprotein: complete response to treatment with alpha-interferon.

Authors:  D S Weinberg; P F Malet
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

Review 2.  Hepatitis C and hepatocellular carcinoma.

Authors:  A M Di Bisceglie
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

3.  Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

Authors:  M L Shiffman; C M Hofmann; E B Thompson; A Ferreira-Gonzalez; M J Contos; A Koshy; V A Luketic; A J Sanyal; A S Mills; C T Garrett
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

4.  A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.

Authors:  M L Shiffman; C M Hofmann; M J Contos; V A Luketic; A J Sanyal; R K Sterling; A Ferreira-Gonzalez; A S Mills; C Garret
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan.

Authors:  M W Yu; S L You; A S Chang; S N Lu; Y F Liaw; C J Chen
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

9.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

Authors:  T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  2 in total

1.  Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.

Authors:  Masakuni Tateyama; Hiroshi Yatsuhashi; Naota Taura; Yasuhide Motoyoshi; Shinya Nagaoka; Kenji Yanagi; Seigo Abiru; Koji Yano; Atsumasa Komori; Kiyoshi Migita; Minoru Nakamura; Hiroyasu Nagahama; Yutaka Sasaki; Yuzo Miyakawa; Hiromi Ishibashi
Journal:  J Gastroenterol       Date:  2010-08-14       Impact factor: 7.527

2.  Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease.

Authors:  Norio Akuta; Yusuke Kawamura; Fumitaka Suzuki; Mariko Kobayashi; Yasuji Arase; Satoshi Saitoh; Nozomu Muraishi; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Yoshiyuki Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatol Int       Date:  2022-03-20       Impact factor: 9.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.